Stock 688513 CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Chengdu Easton Biopharmaceuticals Co., Ltd.

Equities

688513

CNE100004397

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 16/05/2024 BST 		5-day change 1st Jan Change
58.02 CNY -0.99% Intraday chart for Chengdu Easton Biopharmaceuticals Co., Ltd. -5.32% -9.03%
04-22 Chengdu Easton Biopharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-16 Easton Biopharma's Unit Gets Nod to Market Bisoprolol Amlodipine Tablets MT

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 5,715 5,572 7,306 7,659 6,904 - -
Enterprise Value (EV) 1 5,715 5,572 7,306 7,659 6,904 6,904 6,904
P/E ratio 26.7 x 23.9 x 29.7 x 33.9 x 23.9 x 19.3 x 15.3 x
Yield - - - 0.91% 1.31% 1.57% -
Capitalization / Revenue - 5.45 x 6.24 x 6.86 x 4.75 x 3.9 x 3.04 x
EV / Revenue - 5.45 x 6.24 x 6.86 x 4.75 x 3.9 x 3.04 x
EV / EBITDA - 20.1 x 22.9 x 24.2 x 13.6 x 13.2 x 9.59 x
EV / FCF - - - - - - -
FCF Yield - - - - - - -
Price to Book - 2.43 x 2.99 x 2.94 x 2.46 x 2.22 x 2.01 x
Nbr of stocks (in thousands) 120,090 120,090 120,090 120,090 118,999 - -
Reference price 2 47.59 46.40 60.84 63.78 58.02 58.02 58.02
Announcement Date 29/03/21 25/02/22 27/02/23 23/02/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - 1,023 1,171 1,117 1,454 1,771 2,272
EBITDA 1 - 276.8 319 316.5 508 524.5 720
EBIT 1 - 244.2 260.6 243.9 306 389.3 484
Operating Margin - 23.87% 22.27% 21.84% 21.05% 21.99% 21.3%
Earnings before Tax (EBT) 1 - 246.9 262 243.8 308 391 486
Net income 1 178.2 232.4 246.5 226.3 291.3 361.7 457
Net margin - 22.72% 21.06% 20.27% 20.04% 20.42% 20.11%
EPS 2 1.780 1.940 2.050 1.880 2.427 3.010 3.800
Free Cash Flow - - - - - - -
FCF margin - - - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share 2 - - - 0.5800 0.7600 0.9100 -
Announcement Date 29/03/21 25/02/22 27/02/23 23/02/24 - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - -
Net Cash position - - - - - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow - - - - - - -
ROE (net income / shareholders' equity) - 10.6% 10.5% 8.98% 10.4% 11.7% 13.2%
ROA (Net income/ Total Assets) - - - 7.12% 8.1% 8.9% -
Assets 1 - - - 3,180 3,597 4,064 -
Book Value Per Share 2 - 19.10 20.40 21.70 23.50 26.20 28.80
Cash Flow per Share 2 - 1.230 1.270 2.290 4.880 4.620 5.950
Capex 1 - 256 339 175 700 80 -
Capex / Sales - 25.05% 28.96% 15.67% 48.14% 4.52% -
Announcement Date 29/03/21 25/02/22 27/02/23 23/02/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Chengdu Easton Biopharmaceuticals Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
58.02
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD. Stock Chengdu Easton Biopharmaceuticals Co., Ltd.
-9.03% 966M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+32.09% 694B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+29.39% 593B
JOHNSON & JOHNSON Stock Johnson & Johnson
-1.34% 371B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 331B
ABBVIE INC. Stock AbbVie Inc.
+7.39% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.25% 239B
ROCHE HOLDING AG Stock Roche Holding AG
-3.03% 209B
NOVARTIS AG Stock Novartis AG
+10.02% 209B
AMGEN INC. Stock Amgen Inc.
+8.49% 169B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 688513 Stock
  4. Financials Chengdu Easton Biopharmaceuticals Co., Ltd.